BRPI0610038A2 - uso de moduladores seletivos do canal de cloreto para tratar o abuso de substância estimulante e/ou álcool - Google Patents

uso de moduladores seletivos do canal de cloreto para tratar o abuso de substância estimulante e/ou álcool

Info

Publication number
BRPI0610038A2
BRPI0610038A2 BRPI0610038A BRPI0610038A BRPI0610038A2 BR PI0610038 A2 BRPI0610038 A2 BR PI0610038A2 BR PI0610038 A BRPI0610038 A BR PI0610038A BR PI0610038 A BRPI0610038 A BR PI0610038A BR PI0610038 A2 BRPI0610038 A2 BR PI0610038A2
Authority
BR
Brazil
Prior art keywords
chloride channel
relates
treat
alcohol
stimulant
Prior art date
Application number
BRPI0610038A
Other languages
English (en)
Inventor
Sanjay Sabnani
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of BRPI0610038A2 publication Critical patent/BRPI0610038A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0610038A 2005-04-21 2006-04-07 uso de moduladores seletivos do canal de cloreto para tratar o abuso de substância estimulante e/ou álcool BRPI0610038A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/111,435 US20050192271A1 (en) 2003-07-15 2005-04-21 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
PCT/US2006/013155 WO2006115743A2 (en) 2005-04-21 2006-04-07 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Publications (1)

Publication Number Publication Date
BRPI0610038A2 true BRPI0610038A2 (pt) 2016-11-29

Family

ID=37215204

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610038A BRPI0610038A2 (pt) 2005-04-21 2006-04-07 uso de moduladores seletivos do canal de cloreto para tratar o abuso de substância estimulante e/ou álcool

Country Status (17)

Country Link
US (3) US20050192271A1 (pt)
EP (1) EP1742639B1 (pt)
JP (1) JP2008536921A (pt)
KR (1) KR20080004615A (pt)
CN (1) CN101203225A (pt)
AT (1) ATE539755T1 (pt)
AU (1) AU2006240324B2 (pt)
BR (1) BRPI0610038A2 (pt)
CA (1) CA2605918A1 (pt)
CR (1) CR9444A (pt)
IL (1) IL186641A0 (pt)
MX (1) MX2007012993A (pt)
NO (1) NO20075562L (pt)
NZ (1) NZ562585A (pt)
RU (1) RU2007143053A (pt)
WO (1) WO2006115743A2 (pt)
ZA (1) ZA200709048B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
RU2468799C1 (ru) * 2011-08-03 2012-12-10 Общество с ограниченной ответственностью "Урал Крафт" Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same
WO2017210502A1 (en) * 2016-06-03 2017-12-07 Yale University Methods and apparatus for predicting depression treatment outcomes
KR20210039324A (ko) * 2018-04-06 2021-04-09 오비드 테라퓨틱스 인크. 물질 사용 장애들의 치료에서 가복사돌의 사용

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
BR9909290A (pt) * 1998-03-31 2000-12-05 Shinogi Co Processo para preparar derivados de ácido 5-hidroxibenzo [b] tiofeno-3-carboxìlico
AU4100699A (en) 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6750235B1 (en) * 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
ATE338575T1 (de) * 2001-01-17 2006-09-15 Hythiam Inc Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
JP4272885B2 (ja) 2001-02-15 2009-06-03 ハイチアム，インコーポレイテッド コカイン依存症治療用薬剤
US20020150632A1 (en) * 2001-04-12 2002-10-17 Nick Scott Psychonutracological method for craving reduction in humans
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US20030176456A1 (en) * 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
US6740677B2 (en) * 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
ZA200509063B (en) * 2003-05-30 2007-03-28 Titan Pharmaceuticals Inc Impiantable polymeric device for sustained release of nalmefene
JP2005332453A (ja) * 2004-05-19 2005-12-02 Hitachi Ltd 情報再生装置及び情報再生方法
US20060167723A1 (en) * 2005-01-21 2006-07-27 Berg L M Method of treating dependencies
CA2604887A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
NO20075562L (no) 2007-12-07
JP2008536921A (ja) 2008-09-11
US20090215751A1 (en) 2009-08-27
US7863267B2 (en) 2011-01-04
RU2007143053A (ru) 2009-05-27
US20080207599A1 (en) 2008-08-28
ATE539755T1 (de) 2012-01-15
ZA200709048B (en) 2008-09-25
AU2006240324B2 (en) 2010-02-25
US20050192271A1 (en) 2005-09-01
CA2605918A1 (en) 2006-11-02
EP1742639B1 (en) 2012-01-04
NZ562585A (en) 2010-04-30
KR20080004615A (ko) 2008-01-09
WO2006115743A2 (en) 2006-11-02
MX2007012993A (es) 2008-03-11
EP1742639A4 (en) 2008-05-07
IL186641A0 (en) 2008-06-05
CR9444A (es) 2008-02-20
EP1742639A2 (en) 2007-01-17
WO2006115743A3 (en) 2007-06-28
AU2006240324A1 (en) 2006-11-02
CN101203225A (zh) 2008-06-18

Similar Documents

Publication Publication Date Title
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
BR0315979A (pt) Formulação oral de toxina botulìnica e uso da mesma para tratar úlceras pépticas e doença de refluxo gastroesofágico
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
EA201000584A1 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112014016672A2 (pt) compostos de carbamato e sua preparação e uso
BRPI0511477A (pt) compostos e composições como moduladores de ppar
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
EA200900351A1 (ru) Ингибиторы тирозинкиназы брутона
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200801164A3 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
BRPI0508537A (pt) moduladores do canal de ìon
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
ZA200709048B (en) Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20070148387/RJ DE 22/10/2007.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: ANULADA A PUBLICACAO 11.6.1 NA RPI 2178 DE 02/10/2012, POR TER SIDO INDEVIDA

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A PUBLICACAO 6.7 NA RPI 2138 DE 27/12/2011, POR TER SIDO INDEVIDA

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]